Clinical trials: Eye
Myopia, Astigmatism
Prospective Study of an Investigational Toric Soft Contact Lens
The purpose of this study was to demonstrate substantial equivalence of an investigational toric soft contact lens to the commercially available Focus® DAILIES® Toric soft contact lens when worn in a daily wear, daily disposable…
- Conditions
- Myopia, Astigmatism, Refractive Error
- Trial name
- NCT01461811
- Testing
- Nelfilcon A toric contact lenses (with comfort additives), Nelfilcon A toric contact lenses
- Volunteers
- 154 people
- Sponsor
- CIBA VISION
Dry Eye
Systane® Complete Preservative Free Lubricant Eye Drops
The purpose of this post-market clinical follow-up (PMCF) study is to assess the performance and safety of Systane Complete Preservative Free (PF) lubricant eye drops in subjects experiencing dry eye symptoms.
- Trial name
- NCT05932225
- Testing
- Propylene glycol solution/drops
- Where
- 4 sites in Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Retinitis Pigmentosa
A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
The primary objective of the study is to assess the safety and tolerability of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution administered over 6 months versus a vehicle control in patients…
- Trial name
- Lumos (NCT02110225)
- Testing
- rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution
- Where
- 5 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Cataract
Trial Following Subjects Bilaterally Implanted With Mini Well Ready For 2 Years After the Second Eye Implant
The study objective is to evaluate the visual performance of MINI WELL Ready at 24 months following the second eye implant. The objectives of safety are to evaluate the rate of Secondary Surgical Interventions related to the…
- Trial name
- NCT04801992
- Testing
- MINI WELL Ready (SIFI SpA, Italy)
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- SIFI SpA
Allergic Conjunctivitis
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
- Trial name
- NCT01346371
- Testing
- Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minnesota Eye Consultants, P.A.
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Ocular Physiology
Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock
This will be a single-visit, randomized, double-masked, bilateral wear, non-dispensing, 2-sequence × 2-period crossover study to evaluate subject reported ocular symptoms.
- Trial name
- NCT05713552
- Testing
- Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock, Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Cataract, Aphakia
Post-Market Clinical Investigation of the Clareon® IOL
The primary purpose of this study is to evaluate the long-term (3 years) visual acuity and adverse event outcomes for the Clareon® Intraocular Lens (IOL).
- Trial name
- NCT03316885
- Testing
- Clareon® IOL, Cataract Surgery
- Where
- 19 sites in Australia, France and 5 more
- Volunteers
- 245 people
- Sponsor
- Alcon Research
Geographic Atrophy (GA)
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to…
- Trial name
- VIENNA (NCT07230834)
- Testing
- Pozelimab
- Where
- 9 sites in United States, Georgia and 2 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT00882687
- Testing
- Lifitegrast
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shire
Healthy Eyes, Eye Diseases
Triton Agreement and Precision Study
To Compare the agreement and precision between the Topcon DRI OCT Triton and the 3D OCT-1 Maestro with RDB.
- Trial name
- NCT03080714
- Testing
- Topcon DRI OCT Triton (plus), 3D OCT-1 Maestro
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Myopia
Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2
This study is a multi-site, group sequential, adaptive, randomized, double-masked, 2×2 crossover design, 1-week dispensing study.
- Trial name
- NCT03701516
- Testing
- etafilcon A with novel molding process, etafilcon A with current molding process
- Where
- 12 sites in United States
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Dry Eye
Evaluation of Dry Eye by Tear Film Imager in a Low Humidity Environmental Exposure Chamber (TFI-LH16)
The study consists of 3 study visits to the clinic over at least 9 days. Visit 1 - the medical screening visit: subjects will undergo informed consent and will be tested for signs and symptoms of Dry Eye Syndrome (DES) including…
- Trial name
- TFI-LH16 (NCT03061578)
- Testing
- Tear Film Imager, Low Humidity Environmental Exposure Chamber (LH-EEC)
- Where
- Canada
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Adom Advanced Optical Technologies Ltd.
Astigmatism
Bilateral Dispensing Study of MyDay Toric, 1-day Acuvue Moist for Astigmatism, and Dailies Aquacomfort Plus Toric Lenses
Bilateral dispensing study of MyDay Toric, 1-day Acuvue Moist for Astigmatism, and Dailies Aquacomfort Plus Toric lenses
- Trial name
- NCT03134248
- Testing
- Dailies Aquacomfort Plus Toric, 1-Day Acuvue Moist for Astigmatism, MyDay Toric
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- CooperVision, Inc.
Seasonal Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.
- Trial name
- NCT05591755
- Testing
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%
- Where
- 6 sites in United States
- Volunteers
- 229 people
- Sponsor
- Bausch & Lomb Incorporated
Blepharoptosis
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
- Trial name
- NCT03536949
- Testing
- RVL-1201, Vehicle ophthalmic solution
- Where
- 35 sites in United States
- Volunteers
- 234 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Visual Disorders
Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses
This is a multi-site, dispensing, 4-visit, 2-arm parallel group, randomized, double-masked clinical trial using a Vistakon investigational contact lens (test) and a marketed monthly replacement contact lens (control).
- Trial name
- NCT02625233
- Testing
- senofilcon C, comfilcon A
- Where
- 6 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
ROSAH
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
- Trial name
- NCT06395285
- Testing
- DF-003
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Dry Eye Syndrome
Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
- Trial name
- NCT01163643
- Testing
- 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, 1% BOL-303242-X ophthalmic suspension
- Where
- United States
- Volunteers
- 356 people
- Sponsor
- Bausch & Lomb Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.